Arkolith/Insider Trading/RARE/Form 4

Harris Erik

EVP & Chief Commercial OfficerUltragenyx Pharmaceutical Inc. (RARE) · full profile →Form 4 · filed Mar 4, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$636K
Net Open-Market Flow
-$636K
Transactions
4
3 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 3, 2025Sell(S)15K$42.10$636K88K
Mar 1, 2025Grant(A)18K—$0102K
Mar 1, 2025Grant(A)17K—$084K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 1, 2025Grant(A)30K—$030K

Transaction Codes

S
Open-market sale
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000950170-25-032773) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML